Primer: CanSino Biologics (6185 HK) - Aug 2026
CanSino Biologics is at a financial inflection point, having returned to profitability in 2025, driven by the successful commercialization of...
111 Views
𝛼SK or SearchENTITY
CanSino Biologics (6185 HK)
CanSino Biologics (6185 HK)
236
Analysis
Health Care • China
CanSino Biologics is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative vaccine products for human use, primarily focusing on infectious diseases. Its product portfolio includes vaccines for meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, and Ebola virus disease. The company was founded in 2009 and is headquartered in Tianjin, China.
morex